Peptide / Oral GLP-1

Orforglipron

First oral non-peptide GLP-1 receptor agonist. Once-daily pill. Phase 3 trials show similar weight loss to injectable semaglutide. Eliminates injection requirement. Game-changer for adherence. Not yet FDA-approved.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose3mg oral daily → 6mg → 12mg → 24mg.

Half-life12 hours

Risk flaglow

Regulatory noteResearch-only flag

Side effects and watch-outs

Nausea
Diarrhea
Vomiting
Similar GI profile to injectable GLP-1s